About: Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: A screening tool and a point-of-care test

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: A screening tool and a point-of-care test Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: A screening tool and a point-of-care test
Creator	Rueda, Paloma Sastre, Patricia Vela, Carmen Jebbink, Maarten Van Der Hoek, Lia Hoste, Alexis Muñoz, Patricia Almonacid, Mercedes Fresco-Taboada, Alba Guinea, Jesus López, Lissette Monedero, Alejandro Pérez-Ramírez, Elisa Tapia, Istar Venteo, Angel Angel Jimenez-Clavero, Miguel
source	Elsevier; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 8 million people worldwide, becoming a pandemic. Detecting antibodies against SARS-CoV-2 is of utmost importance and a good indicator of exposure and circulation of the virus within the general population. Two serological tools based on a Double Recognition assay (Enzyme-Linked Immunosorbent Assay, DR-ELISA and Lateral Flow Assay, DR-LFA) to detect total antibodies to SARS-CoV-2, have been developed based on the recombinant nucleocapsid protein. A total of 1065 serum samples, including positive for COVID-19 and negative samples from healthy donors or infected with other respiratory pathogens, were analyzed. The results showed values of sensitivity between 91.2%–100%, and specificity of 100%–98.2%, for DR-LFA and DR-ELISA, respectively. No cross-reactivity against seasonal coronavirus (HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43) was found. These results demonstrate the importance of serology as a complementary tool to PCR, for follow up of recovered patients and identification of asymptomatic individuals.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1016/j.diagmicrobio.2020.115167
has license	no-cc
sha1sum (hex)	c0c7c4d443e26d057af219d4b952d1602245e670
schema:url	https://doi.org/10.1016/j.diagmicrobio.2020.115167
resource representing a document's title	Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: A screening tool and a point-of-care test
has PubMed Central identifier	PMC7417941
schema:publication	Diagn Microbiol Infect Dis
resource representing a document's body	covid:c0c7c4d443e26d057af219d4b952d1602245e670#body_text
is schema:about of	named entity 'infection' named entity 'PCR' named entity 'SARS-CoV-2' named entity 'nucleocapsid' named entity 'nitrocellulose' named entity 'N-Hydroxysuccinimide' named entity 'plasma' named entity 'molecule' named entity 'nucleocapsid' named entity 'latex' named entity 'nitrocellulose' named entity 'infection' named entity 'serological' named entity 'RT-PCR' named entity 'coronavirus' named entity 'RT-PCR' named entity 'carbodiimide' named entity 'infection' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'IgM' named entity 'serum' named entity 'diagnostic tool' named entity 'IgM' named entity 'IgM' named entity 'IgM' named entity 'Mycoplasma pneumonia' named entity 'infection' named entity 'serological' named entity 'point-of-care test' named entity 'serum' named entity 'NaCl' named entity 'nucleocapsid' named entity 'recombinant' named entity 'nucleocapsid' named entity 'enzyme' named entity 'latex' named entity 'antigen' named entity 'point-of-care test' named entity 'IgM' named entity 'serum samples' named entity 'infection' named entity 'molecule' named entity 'infection' named entity 'antibodies' named entity 'IgG' named entity 'serological' named entity 'pathogens' named entity 'SARS-CoV-2' named entity 'virus' named entity 'virus' named entity 'protein' named entity 'social distance' named entity 'morbidity' named entity 'SARS' named entity 'coronaviruses' named entity 'IgG' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'pH 9' named entity 'serological' named entity 'hygiene measures' named entity 'virus' named entity 'IgG' named entity 'infectious diseases' named entity 'animal species'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software